United States Army Medical Research and Development Command

Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens

Retrieved on: 
Wednesday, October 25, 2023
CRADA, Ageing, Cooperative research and development agreement, Therapy, Maxwell, United States Army Medical Research and Development Command, Biological warfare, U.S. Army Public Health Center, United States Army Medical Research Institute of Infectious Diseases, Development, USAMRIID, McClure, Infection, Peptide, Vaccine

USAMRIID to study antiviral activity of Claromer technology against national priority biodefense threats

Key Points: 
  • Part of the U.S. Army Medical Research and Development Command, USAMRIID is the U.S Army's premier institution and facility for defensive research into countermeasures against biological warfare, located on Fort Detrick, Maryland.
  • "As a military veteran, I'm proud to lead a team that tirelessly seeks to fill critical unmet needs for more effective therapeutics against the worst global pathogens."
  • "Our Claromer technology has the potential to replace almost all antibiotics, antifungals and antivirals - and it may help with healthy aging as well," continued McClure.
  • "Signing this CRADA with USAMRIID, the world's preeminent biodefense research organization, is another validation of Maxwell's Claromer technology's potential as an important, disruptive platform technology."

Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors

Retrieved on: 
Wednesday, October 18, 2023
Storm, Biomedical Advanced Research and Development Authority, Global health, United States Army Nurse Corps, Certification, Civilization, Defense Advanced GPS Receiver, United States Army War College, Medicine, Kosovo Force, Combat support hospital, RN, Commanding officer, Health, Development, American Public University System, Disease, BioBridge Global, RET, University of Kansas, USAMRIID, University, Fort Detrick, National security, Pandemic, United States Army Medical Research and Development Command, ROTC, Infection, Texas Desert Shield-Desert Storm Campaign Medal, BSN, MSN, Scientific Committee on Oceanic Research, Operation New Dawn, 67th Combat Support Hospital (United States), Nursing, Operation, DARPA

Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.

Key Points: 
  • Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.
  • This appointment adds one of the world's top national security and biodefense research and logistics executives to Maxwell's board.
  • "I am pleased to welcome General Holcomb's leadership in national security and patient care to Maxwell's board as we approach human trials next year," said Maxwell Biosciences Chairman and CEO Joshua McClure.
  • "General Holcomb is a highly patient-focused medical professional with decades of deep respect within the global and national security biodefense communities.

OREF, MTEC, DOD Select Recipients of $2 Million Research Award Collaboration

Retrieved on: 
Tuesday, October 24, 2023
Education, Health, ACL, Orthopaedic Research Society, Human musculoskeletal system, Musculoskeletal injury, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Army Medical Research and Development Command, Doctor of Philosophy, Research, Military medicine, Injury, Quality of life, Anterior cruciate ligament, DOD, Partnership, Woman, The Foundation for Young Australians, Defense, Patient, MTEC, Knee pain, Pharmaceutical industry, Nursing, MD, United States Army, Service

ROSEMONT, Ill., Oct. 24, 2023 /PRNewswire-PRWeb/ -- The Orthopaedic Research and Education Foundation (OREF), in collaboration with the Medical Technology Enterprise Consortium (MTEC) and the Department of Defense's (DOD) U.S. Army Medical Research and Development Command's (USAMRDC) Military Operational Medicine Research Program (MOMRP), today announced selection for recipients of the OREF/MTEC Request for Project Proposals entitled, "MTEC-23-02-MSKI, Solutions to Accelerate Return-to-Readiness following Musculoskeletal Injuries." The program provides $2 million in research and development funding. OREF is contributing $100,000 toward the awards, which was made possible by a generous gift from The Aircast Foundation, a private foundation committed to promoting and supporting excellence in scientific and clinical research and education in the area of orthopaedic medicine. The remainder of the funding is provided by the DOD.

Key Points: 
  • Recipients will utilize the funds for research leading to the advancement of solutions to accelerate return-to-readiness for Service Members experiencing musculoskeletal injuries.
  • The program provides $2 million in research and development funding.
  • OREF is excited to collaborate with MTEC and MOMRP to fund research that may accelerate return-to-readiness for Service members affected by musculoskeletal injuries."
  • "An important component of the public-private collaboration that MTEC fosters is the ability to leverage philanthropic dollars to serve military medical need.

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
Friday, October 13, 2023
Mount Sinai, Icahn School of Medicine at Mount Sinai, Contract research organization, Internal medicine, MS, Abstract, Research, VARSITY, The New England Journal of Medicine, Crohn's and Colitis Canada, Therapy, IBD, Safety, University, Inflammatory bowel disease, Annals of Internal Medicine, JAMA, Inflammatory Bowel Diseases, Publication, United States Army Medical Research and Development Command, Dean, Patient, Pharmaceutical industry, MD, Nature, Medicine, Lancet

LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
Friday, October 13, 2023
Mount Sinai, Icahn School of Medicine at Mount Sinai, Contract research organization, Internal medicine, MS, Abstract, Research, VARSITY, The New England Journal of Medicine, Crohn's and Colitis Canada, Therapy, IBD, Safety, University, Inflammatory bowel disease, Annals of Internal Medicine, JAMA, Inflammatory Bowel Diseases, Publication, United States Army Medical Research and Development Command, Dean, Patient, Pharmaceutical industry, MD, Nature, Medicine, Lancet

LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Retrieved on: 
Tuesday, September 26, 2023
Defense Health Agency, U.S. Department of Defense Strategy for Operating in Cyberspace, Bromelain (pharmacology), United States Department of Defense, Temperature, Burn, United States Department of the Army, United States Army Medical Research and Development Command, Biomedical technology, MTEC, Pharmaceutical industry, Defense

The $6.5 million project budget will advance the development of a new, temperature stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings.

Key Points: 
  • The $6.5 million project budget will advance the development of a new, temperature stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings.
  • “We are honored to further our collaboration with the U.S. Department of Defense.
  • Our shared vision of enhancing treatment outcomes for traumatic burns on the battlefield will ensure NexoBrid's availability for military use,” said Ofer Gonen, Chief Executive Officer of MediWound.
  • In alignment with this mission, it's vital to have field solutions for severe burn treatments that are both easy-to-use and effective.

The Inner Circle Acknowledges, Althea Green as a Top Pinnacle Professional for her contributions to the field of Academia

Retrieved on: 
Friday, August 25, 2023
Walter Reed Army Medical Center, Senior enlisted advisor, United States Department of the Army, Air Command and Staff College, Army, Life, Woman, Multimedia, Inner circle, Senior Enlisted Advisor to the Chairman, Distinguished service medal, Command General Staff College Foundation, United States Army Medical Command, Recruitment, Investment, United States Department of Defense, Order of Military Medical Merit, Department of Defense Instruction 1300.28, Love, United States Army Medical Research and Development Command, Enlisted, LE, Environment, Management, Nursing, Medicine

CLARKSBURG, Md., Aug. 24, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Althea Green is acknowledged as a Top Pinnacle Professional for her contributions to the field of Academia.

Key Points: 
  • CLARKSBURG, Md., Aug. 24, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Althea Green is acknowledged as a Top Pinnacle Professional for her contributions to the field of Academia.
  • Dr. Green attributes her success primarily to her open-mindedness and eagerness to embrace new challenges and opportunities for personal growth.
  • A civic-minded servant, Dr. Green focuses her efforts on supporting women transitioning to civilian life after military service.
  • Dr. Green would like to gratefully dedicate this honor to her beloved husband, Larry Johnson, and her cherished children.

Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT

Retrieved on: 
Thursday, July 6, 2023
Antigen, Human, AMED, NEDO, Cone Health Women's Hospital, Teaching, New Energy and Industrial Technology Development Organization, Acute lymphoblastic leukemia, Cabinet Office, Massachusetts General Hospital, Research, Dopamine, Kyoto, Behavior, Lymphoma, MGB, Regenerative medicine, Harvard Medical School, Transplant, Department of Neurobiology, Harvard Medical School, Innovation Center station, Digital technology, Innovation system, Protein, Hospital, Parkinson's disease, MEXT, MD, Mass, FIRST, Immune system, Kyoto University, Cancer, Mass General Brigham, BWH, Ecosystem, Longevity, Rare, GCT, IPS, Gene, Medical research, United States Army Medical Research and Development Command, TSE, Disease, Pharmaceutical industry, Vaccine, Renewable energy, Science, Brigham

By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.

Key Points: 
  • By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.
  • Hitachi will also contribute to the advancement of GCT through cell culturing and the development of the culturing process required in GCT by bringing research achievements and business experience in the field of regenerative medicine and GCT.
  • Mass General Brigham is a world-leading eco-system for GCT research and clinical trials, with over 400 researchers working on ground-breaking gene and cell therapy research and treatment in pursuit of potential cures.
  • From an early stage, Mass General Brigham has been actively engaged in GCT research, creating GCTI in December 2022.

PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome

Retrieved on: 
Tuesday, August 1, 2023
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, PRTC, LSE, Defense Health Agency, University of California, Davis, Tremor, Anxiety, University, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Ageing, PureTech Health, FMR1, Research, Medicine, Development director, Element, Veteran, CNS, Dementia, Trial of the century, Science, Assistant, Intellectual disability, FXS, Fragile X syndrome, UC, Patient, Department of Defense Serum Repository, United States Army Medical Research and Development Command, Spectrum, United States Army Medical Research Institute of Infectious Diseases, MIND Institute, FXTAS, Office of the Assistant Secretary for Health, Assistant Secretary of Defense for Health Affairs, Glyph, Cannabidiol, Safety, Allopregnanolone, Pharmaceutical industry, Vaccine, Defense, Fragile

The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).

Key Points: 
  • The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).
  • Both conditions are the result of repeated elements in the Fragile X Messenger Ribonucleoprotein Gene 1 (FMR1) gene.
  • Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.
  • In addition to LYT-300, which is being advanced in three indications, PureTech is progressing multiple CNS-focused programs derived from its Glyph platform.

Defender Pharmaceuticals Announces Exclusive License Agreement with the U.S. Army for the Development of Products to Treat Tropical Diseases

Retrieved on: 
Monday, July 31, 2023
Q fever, Regulated Activation Networks, United States Army Medical Materiel Agency, Tularemia, Licensure, United States Army Medical Research and Development Command, Chikungunya, Investigational New Drug, Venezuelan equine encephalitis virus, United States Department of the Army, Government, Rift Valley fever, Disease, Pharmaceutical industry, Defender

Medical Research and Development Command (USAMRDC), to develop and commercialize a total of eight products for use against the following tropical diseases: tularemia (rabbit virus); Venezuelan Equine Encephalitis (two formulations); Eastern Equine Encephalitis; Western Equine Encephalitis; Rift Valley Fever; chikungunya and Q Fever.

Key Points: 
  • Medical Research and Development Command (USAMRDC), to develop and commercialize a total of eight products for use against the following tropical diseases: tularemia (rabbit virus); Venezuelan Equine Encephalitis (two formulations); Eastern Equine Encephalitis; Western Equine Encephalitis; Rift Valley Fever; chikungunya and Q Fever.
  • The agreement was entered into on July 25th, 2023 and covers eight investigational vaccines that have been part of the Army’s Special Immunization Program.
  • Under the agreement, USAMMDA will transfer the Investigational New Drug applications for each of the eight products, related data, and biological materials to Defender.
  • Development work on these products will commence once this transfer is complete.